Another interesting field, which is my own, is cofactors, not only to the disease but also to transmission. I am still puzzled by the fact that you get more sexual transmission in some ethnic populations. One way to answer this is to look for genetic factors.

It's clear that prevention will never be sufficient. That's why we need a vaccine that will be safe.

The idea of the live-virus vaccine is to produce in a continuous way some viral antigens.

My proposal now is to test a vaccine first on people who have been infected, and if you show some efficacy at this level, you might be able to go further to study uninfected people in a population with a high rate of infection.

The center will be fully operational in two years' time, but probably in the middle of the year we will have a temporary laboratory of 4,000 square feet.

We don't know why, but there are some gradients of infection.

Our goal is not to completely eradicate the infection - that would be very difficult - but to produce a vaccine that will prevent not infection but disease. I think this is more possible.